Establishment of a ccRCC patient-derived chick chorioallantoic membrane model for drug testing

• Published in: Frontiers in medicine 2022-10, Vol.9, p.1003914-1003914
• Main Authors: Charbonneau, Martine, Harper, Kelly, Brochu-Gaudreau, Karine, Perreault, Alexis, McDonald, Patrick P., Ekindi-Ndongo, Nadia, Jeldres, Claudio, Dubois, Claire M.
• Format: Article
• Language: English
• Subjects: animal models; CAM assay; ccRCC; chick chorioallantoic membrane; Medicine; patient-derived xenograft (PDX); sunitinib
• ISSN: 2296-858X; 2296-858X
• DOI: 10.3389/fmed.2022.1003914

Clear cell renal cell carcinoma (ccRCC) is an aggressive subtype of renal cell carcinoma accounting for the majority of deaths in kidney cancer patients. Advanced ccRCC has a high mortality rate as most patients progress and develop resistance to currently approved targeted therapies, highlighting the ongoing need for adequate drug testing models to develop novel therapies. Current animal models are expensive and time-consuming. In this study, we investigated the use of the chick chorioallantoic membrane (CAM), a rapid and cost-effective model, as a complementary drug testing model for ccRCC. Our results indicated that tumor samples from ccRCC patients can be successfully cultivated on the chick chorioallantoic membrane (CAM) within 7 days while retaining their histopathological characteristics. Furthermore, treatment of ccRCC xenografts with sunitinib, a tyrosine kinase inhibitor used for the treatment of metastatic RCC, allowed us to evaluate differential responses of individual patients. Our results indicate that the CAM model is a complementary in vivo model that allows for rapid and cost-effective evaluation of ccRCC patient response to drug therapy. Therefore, this model has the potential to become a useful platform for preclinical evaluation of new targeted therapies for the treatment of ccRCC.